Updated EASO Framework for Obesity Pharmacotherapy : Nat Med | May 2026

Introduction

Obesity is increasingly recognized as a chronic, relapsing, multisystem disease requiring long-term, complication-oriented management rather than a purely weight-centric approach. The rapid expansion of anti-obesity pharmacotherapy, particularly incretin-based therapies and emerging combination agents, has substantially altered the therapeutic landscape. This 2026 update from the European Association for the Study of Obesity refines the European framework for obesity treatment by integrating new evidence regarding weight reduction, cardiometabolic outcomes and obesity-associated liver disease.

Problem Statement

Traditional obesity management algorithms relied heavily on body mass index thresholds and often underestimated the heterogeneity of obesity-related complications. The emergence of highly effective pharmacologic therapies has created uncertainty regarding optimal patient selection, treatment sequencing, duration of therapy and integration with metabolic, cardiovascular and hepatic risk stratification. In addition, obesity-related complications such as Metabolic Dysfunction-Associated Steatotic Liver Disease and Type 2 Diabetes increasingly require coordinated multidisciplinary treatment approaches.

Summary

This updated EASO framework emphasizes a complication-centric model of obesity care that prioritizes improvement in obesity-related disease burden rather than weight loss alone. The document highlights obesity as a biologically regulated chronic disease involving neuroendocrine, metabolic, inflammatory and behavioral pathways, thereby supporting earlier and more individualized pharmacologic intervention. The updated algorithm incorporates recent evidence from incretin-based therapies, particularly GLP-1 receptor agonists and dual incretin agonists, which now achieve weight reductions previously attainable mainly through bariatric surgery.

The framework strongly advocates comprehensive baseline assessment including adiposity distribution, cardiometabolic risk, liver disease, sleep disorders, musculoskeletal disease and psychological health. Pharmacologic therapy is recommended not only according to BMI but also according to obesity-related complications and disease severity. Patients with established cardiovascular disease, MASLD/MASH, obstructive sleep apnea or diabetes are prioritized for early pharmacotherapy escalation because these populations derive substantial metabolic and organ-specific benefits beyond weight reduction alone.

A major update in the 2026 guidance is the integration of emerging liver disease evidence. The framework recognizes the growing role of obesity pharmacotherapy in improving hepatic steatosis, metabolic dysfunction-associated steatohepatitis and fibrosis risk. GLP-1–based therapies are increasingly positioned as important therapeutic options for patients with obesity-associated liver disease, particularly when accompanied by diabetes or cardiometabolic dysfunction. The document also acknowledges the evolving role of combination therapies and future precision-based obesity medicine targeting specific biological phenotypes.

Importantly, EASO emphasizes that pharmacotherapy should be integrated with structured lifestyle intervention rather than viewed as a replacement for behavioral treatment. Nutritional optimization, physical activity, sleep regulation and psychological support remain foundational. The framework also highlights the importance of preserving lean muscle mass during substantial pharmacologically induced weight loss through adequate protein intake and resistance exercise.

The update further addresses the chronicity of obesity treatment, recognizing that discontinuation of therapy commonly results in weight regain and recurrence of metabolic complications. Long-term maintenance therapy is therefore increasingly viewed analogously to treatment strategies for hypertension or diabetes. Overall, the 2026 EASO framework reflects a major shift toward personalized, complication-driven obesity care integrating metabolic, cardiovascular and hepatic outcomes into therapeutic decision-making.